Developer docs
API playgroundTry for free, no card

Search company profiles

Molzym

Full company profile

uuid000i4k4

Namestring
Molzym
Legal namestring
Molzym GmbH & Co. KG
Websiteurl
molzym.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Molzym GmbH & Co. KG is a privately held molecular diagnostics company headquartered in Bremen, Germany, founded in 2003 and acquired by Bruker Corporation in November 2025. The company develops and sells culture-independent diagnostic and life-science research products for the detection and identification of bacterial and fungal pathogens directly from clinical specimens. Its core technology platform is the proprietary MolYsis™ method, which selectively depletes up to 99% of human host DNA from clinical samples (whole blood, cerebrospinal fluid, joint aspirates, tissue biopsies) via selective host cell lysis and nuclease digestion, while preserving microbial cells through their rigid cell walls — enabling downstream broad-range 16S (bacteria) and 18S (fungi) rRNA gene PCR and Sanger sequencing identification against a curated BLAST reference database of more than 7,000 bacterial and 340 fungal species.

The product portfolio spans CE-IVD-marked clinical diagnostics (SepsiTest™-UMD manual kit, Micro-Dx™ on SelectNA™plus, and the IVDR-compliant MolYsis-SNplus™ IVD), a fully automated SelectNA™plus bench-top robot for walk-away microbial DNA extraction (1-12 samples per run), research-use reagents including DNA-free PCR master mixes (MolTaq, Hot MolTaq, Mastermix 16S/18S), and Ultra-Deep Microbiome Prep kits for NGS applications. Services include mastermix purification, free SepsiTest™ BLAST sequence analysis, and licensing of Molzym's host DNA removal and PCR decontamination know-how. The company holds EN ISO 13485 certification, IVDR compliance, and an FDA Breakthrough Device Designation for its molecular diagnostic system covering sepsis, joint and implant infections, infective endocarditis, and bacterial meningitis.

Molzym operates a sales-led go-to-market model: direct sales in Germany and a distributor network covering approximately 30 countries, with named regional partners across Europe, North America, Asia Pacific (China, Japan, Korea, Singapore, Taiwan, India), the Middle East, and Africa. Pricing is quote-based across all products with no public list prices. Customers include clinical laboratories, hospital microbiology departments, and academic research institutions, with documented use cases at Labor Berlin – Charité Vivantes, Johns Hopkins School of Medicine, and LMU Munich. Revenue is generated from one-time sales of IVD kits, life-science consumables, instruments, and recurring services/licensing. The company has 11-50 employees and previously raised a double-digit million EUR capital increase from a single family office in June 2022 to fund US and China market entry.

Short descriptiontext

Molzym GmbH & Co. KG, founded in 2003 in Bremen, Germany and acquired by Bruker Corporation in 2025, develops CE-IVD-marked molecular diagnostic kits and automated instruments (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD, SelectNA™plus) for culture-independent detection of bacterial and fungal pathogens in clinical specimens, sold to hospitals, clinical laboratories, and research institutions in approximately 30 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBremen, Germany
HQ citystring
Bremen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular pathogen diagnostics, clinical IVD kits, host DNA depletion, microbiome analysis reagents, automated DNA extraction
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Molecular Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1IVD Diagnostic Kits
TypeOne Time License
Description

Sale of CE IVD-marked diagnostic kits including SepsiTest™-UMD and Micro-Dx™ for culture-independent pathogen detection in clinical specimens. These kits include reagents for human DNA depletion, microbial DNA isolation, and 16S/18S PCR assays.

molzym.com
2Life Science Research Products
TypeOne Time License
Description

Sale of research-use products including MolYsis™ kits for host DNA depletion, DNA-free PCR reagents (MolTaq, Hot MolTaq, Mastermix), Ultra-Deep Microbiome Prep kits for NGS applications, and SelectNA™plus instruments.

molzym.com
3Services
TypeProfessional Services
Description

Services include Mastermix Purification Service for decontamination of customer master mixes, Sequence Analysis Software (SepsiTest™ BLAST), and licensing opportunities for Molzym's technologies including host DNA removal methods and PCR decontamination know-how.

molzym.com
4Instrument Sales
TypeHardware Sales
Description

Sale of SelectNA™plus robotic instruments for automated microbial DNA extraction. Instruments are sold alongside consumable kits for ongoing revenue.

molzym.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel
Pricing details1 tier
1Quote-based pricing for all products
ModelOtherBilling cadencePay-as-you-go
Notes

All products are sold via quote request system. No public pricing available. Contact information provided for direct inquiries: info.molzym@bruker.com, order.molzym@bruker.com

molzym.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Molzym develops, manufactures, and sells molecular diagnostic kits, instruments, and reagents for culture-independent detection of bacterial and fungal pathogens. The portfolio centers on the proprietary MolYsis™ host DNA depletion technology combined with broad-range 16S/18S rRNA PCR assays, sold as CE IVD-marked clinical diagnostic products (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD) and as life science research kits (MolYsis™ Basic5, Ultra-Deep Microbiome Prep, DNA-free PCR reagents), supported by the SelectNA™plus automated extraction robot and the SepsiTest™ BLAST online identification software.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 89% diagnostic sensitivity (95% CI: 83.8 to 94.2%) and 85% specificity (95% CI: 76.5 to 93.5%) in 409 comparative analyses
+3 more records
Product overview1 text field

Molzym offers a comprehensive portfolio of molecular diagnostic and life science products focused on culture-independent pathogen detection. The portfolio is organized into Clinical Diagnostics (CE IVD-marked products) and Life Science (research use products) categories. Key products include SepsiTest™-UMD CE IVD for manual molecular pathogen diagnosis, Micro-Dx™ CE IVD for automated diagnosis using the SelectNA™plus robot, and MolYsis-SN*plus*™ IVD for automated DNA isolation. The MolYsis™ technology platform enables host DNA depletion for improved molecular analysis. Supporting products include DNA-free PCR reagents (MolTaq, Hot MolTaq, Mastermix products), Ultra-Deep Microbiome Prep kits for NGS applications, and standard Taq DNA polymerases. Services include mastermix purification, sequence analysis software (SepsiTest™ BLAST), and licensing opportunities. The company was acquired by Bruker Corporation in late 2025.

Product and service15 records
1SepsiTest™-UMD CE IVD
CategoryClinical Diagnostic Product
Description

CE IVD-marked molecular test kit for culture-independent detection and identification of bacterial and fungal pathogens in body fluids, tissues, and swabs via 16S and 18S rRNA gene PCR and Sanger sequencing, for clinical laboratories performing molecular infectious disease diagnostics.

2Micro-Dx™ CE IVD
CategoryClinical Diagnostic Product
Description

Fully automated pathogen DNA enrichment and isolation system combining the SelectNA™plus robot with broad-range 16S and 18S PCR assays, designed for routine molecular diagnosis of bacterial and fungal pathogens in clinical laboratories.

3MolYsis-SN*plus*™ IVD
CategoryClinical Diagnostic Product
Description

IVDR-compliant, fully automated kit for human DNA depletion and bacterial/fungal DNA isolation from diverse clinical specimens, used with the SelectNA™plus instrument for clinical diagnostic workflows.

4SelectNA™plus Robot
CategoryInstrument
Description

Bench-top robotic instrument for fully automated microbial DNA extraction from clinical specimens, with capacity for 1-12 samples per run and integrated UV decontamination.

5MolYsis™ Basic5
CategoryLife Science Product
Description

Manual research-use kit for host DNA depletion from liquid biopsies (0.2-1 ml or 5 ml volumes), combinable with any microbial DNA isolation kit, for life science researchers.

6MolYsis™ Complete5
CategoryLife Science Product
Description

Complete manual research-use kit combining host DNA depletion and microbial DNA isolation from liquid biopsies with validated protocols for life science researchers.

7Ultra-Deep Microbiome Prep
CategoryLife Science Product
Description

Research-use kit for host DNA depletion and microbial DNA isolation from 0.2-1 ml liquid samples or tissue specimens for next-generation sequencing (NGS) microbiome analysis.

8Ultra-Deep Microbiome Prep10
CategoryLife Science Product
Description

Research-use kit for host DNA depletion and microbial DNA isolation from 1-10 ml liquid samples or tissue specimens for deeper NGS microbiome analysis.

9MolYsis-SelectNA™plus
CategoryLife Science Product
Description

Automated research-use kit for enrichment and isolation of microbial DNA from body fluids, tissues, and swabs using the SelectNA™plus robot.

10DNA-Free PCR Reagents (MolTaq, Hot MolTaq, Mastermix 16S/18S Basic, Mastermix 16S/18S Dye, Mastermix 16S Complete, Mastermix 18S Complete, DNA-free Water)
CategoryLife Science Product
Description

DNA-free PCR reagents line including MolTaq 16S/18S DNA polymerases, Hot MolTaq polymerase, Mastermix products (Basic, Dye, 16S Complete, 18S Complete), and PCR-grade DNA-free water, validated for up to 40 amplification cycles without false positive background.

11MolTaq Standard PCR Reagents
CategoryLife Science Product
Description

Standard highly processive Taq DNA polymerase for routine PCR applications with 5'-3' exonuclease activity, sold under the MolTaq brand.

12UMD-Tubes
CategoryResearch Use Product
Description

Research-use cryo-protectant vials for long-term storage of clinical fluid samples at -70 to -80°C, protecting pathogens from freeze-thaw damage.

13Mastermix Purification Service
CategoryService
Description

Custom service for setup and decontamination of customer master mixes, leveraging Molzym's DNA-free reagent expertise to ensure optimal assay performance without reagent contamination.

14SepsiTest™ BLAST Sequence Analysis Software
CategoryService
Description

Free online BLAST bioinformatics tool for 16S and 18S rDNA sequence analysis, containing quality-edited full-length sequences of 7,042 cultivated bacteria and 342 cultivated fungi for species-level pathogen identification.

15Technology Licensing Program
CategoryService
Description

Licensing program offering access to Molzym's proprietary host DNA removal methods and PCR decontamination know-how for assay development by partner companies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Molzym was acquired by Bruker Corporation in late 2025 (announced November 26, 2025). This acquisition strengthens Bruker's portfolio in molecular diagnostics and clinical research. Molzym operations continue as usual with same products, services, and supply processes. Contact emails updated to @bruker.com domain.

2French Society of Microbiology (SFM)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-13
Description

Partnership announced December 2022 to promote and stimulate the field of microbiology. Both organizations share desire to create synergies with experts to develop innovative and clinically relevant solutions for microbiology and infectious disease actors.

molzym.com
3Fraunhofer IZI-BB
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-02
Description

Joint research and development project funded by European Regional Development Fund (ERDF) and federal state of Brandenburg (ILB) to develop automated sepsis diagnostic (AutoSepT) for fast testing in clinical laboratories.

molzym.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-12-16
Description

Molzym joined Gradian Diagnostics in December 2019. Gradian is a holding company based in Miami, USA working on expanding diagnostic solutions through acquisitions. Molzym's team, locations, and operations remained unchanged following this acquisition.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Parent company since late 2025 and broader life sciences tools and diagnostics company; MALDI Biotyper provides culture-based microbial ID that complements or competes with Molzym's culture-independent approach within the same microbiology workflows and customer base.

TypeDirect peer
Description

Swedish diagnostics company developing the ASTar system for rapid antimicrobial susceptibility testing directly from clinical samples; directly competes in culture-independent pathogen diagnostics for bloodstream infections with comparable technology positioning.

TypeDirect peer
Description

Maker of the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing (AST) directly from positive blood cultures; directly comparable as a rapid molecular/fluorometric diagnostics company targeting bloodstream infection diagnostics in similar clinical indications.

TypeDirect peer
Description

Developer of cell-free DNA next-generation sequencing-based pathogen detection from blood; directly comparable as an unbiased molecular pathogen diagnostics company serving similar clinical indications including sepsis and difficult-to-diagnose infections.

TypeBroad incumbent
Description

Developer of the GeneXpert molecular diagnostics platform with broad syndromic panels for infectious disease; competes as a larger incumbent with established hospital sales channels and FDA-cleared pathogen detection assays serving similar clinical laboratory customers.

TypeBroad incumbent
Description

Broad women's health and molecular diagnostics company with the Panther Fusion and Panther platforms for infectious disease testing; acquired Mobidiag in 2022 adding molecular GI infection diagnostics, positioning as a larger competitor in molecular pathogen detection.

TypeDirect peer
Description

Global leader in clinical microbiology diagnostics, including the BioFire FilmArray syndromic molecular panels and VITEK mass spectrometry ID; directly comparable as a microbiology-focused diagnostics company with overlapping pathogen detection offerings and similar hospital laboratory customers.

TypeDirect peer
Description

Developer of the REVEAL Rapid ID/AST system using proprietary volatile metabolomics for culture-free pathogen identification; overlaps with Molzym's culture-independent diagnostic approach for serious infections and similar hospital laboratory customers.

TypeDirect peer
Description

Developer of T2 Magnetic Resonance-based molecular diagnostics for bloodstream infections (T2Bacteria, T2Candida); directly competes in culture-independent pathogen detection from whole blood with similar sepsis diagnostic value proposition and clinical workflow.

TypeBroad incumbent
Description

Global molecular diagnostics and sample technologies company with the QIAstat-Dx syndromic panel system; competes as a broader incumbent offering pathogen detection workflows across multiple sample types and clinical indications, with overlapping customer base in clinical microbiology laboratories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molzym

In Vitro Molecular Diagnosticsmolzym.com

Molzym GmbH & Co. KG, founded in 2003 in Bremen, Germany and acquired by Bruker Corporation in 2025, develops CE-IVD-marked molecular diagnostic kits and automated instruments (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD, SelectNA™plus) for culture-independent detection of bacterial and fungal pathogens in clinical specimens, sold to hospitals, clinical laboratories, and research institutions in approximately 30 countries.

What Molzym does

Molzym GmbH & Co. KG is a privately held molecular diagnostics company headquartered in Bremen, Germany, founded in 2003 and acquired by Bruker Corporation in November 2025. The company develops and sells culture-independent diagnostic and life-science research products for the detection and identification of bacterial and fungal pathogens directly from clinical specimens. Its core technology platform is the proprietary MolYsis™ method, which selectively depletes up to 99% of human host DNA from clinical samples (whole blood, cerebrospinal fluid, joint aspirates, tissue biopsies) via selective host cell lysis and nuclease digestion, while preserving microbial cells through their rigid cell walls — enabling downstream broad-range 16S (bacteria) and 18S (fungi) rRNA gene PCR and Sanger sequencing identification against a curated BLAST reference database of more than 7,000 bacterial and 340 fungal species.

The product portfolio spans CE-IVD-marked clinical diagnostics (SepsiTest™-UMD manual kit, Micro-Dx™ on SelectNA™plus, and the IVDR-compliant MolYsis-SNplus™ IVD), a fully automated SelectNA™plus bench-top robot for walk-away microbial DNA extraction (1-12 samples per run), research-use reagents including DNA-free PCR master mixes (MolTaq, Hot MolTaq, Mastermix 16S/18S), and Ultra-Deep Microbiome Prep kits for NGS applications. Services include mastermix purification, free SepsiTest™ BLAST sequence analysis, and licensing of Molzym's host DNA removal and PCR decontamination know-how. The company holds EN ISO 13485 certification, IVDR compliance, and an FDA Breakthrough Device Designation for its molecular diagnostic system covering sepsis, joint and implant infections, infective endocarditis, and bacterial meningitis.

Molzym operates a sales-led go-to-market model: direct sales in Germany and a distributor network covering approximately 30 countries, with named regional partners across Europe, North America, Asia Pacific (China, Japan, Korea, Singapore, Taiwan, India), the Middle East, and Africa. Pricing is quote-based across all products with no public list prices. Customers include clinical laboratories, hospital microbiology departments, and academic research institutions, with documented use cases at Labor Berlin – Charité Vivantes, Johns Hopkins School of Medicine, and LMU Munich. Revenue is generated from one-time sales of IVD kits, life-science consumables, instruments, and recurring services/licensing. The company has 11-50 employees and previously raised a double-digit million EUR capital increase from a single family office in June 2022 to fund US and China market entry.

Molzym firmographics

Firmographics
Name
Molzym
Legal name
Molzym GmbH & Co. KG
Website
https://molzym.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Molzym GmbH & Co. KG, founded in 2003 in Bremen, Germany and acquired by Bruker Corporation in 2025, develops CE-IVD-marked molecular diagnostic kits and automated instruments (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD, SelectNA™plus) for culture-independent detection of bacterial and fungal pathogens in clinical specimens, sold to hospitals, clinical laboratories, and research institutions in approximately 30 countries.
Ownership category
akta.pro rank

Molzym industry classification

Industry
Product category
In Vitro Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Molecular pathogen diagnostics
  • Clinical IVD kits
  • Host DNA depletion
  • Microbiome analysis reagents
  • Automated DNA extraction

Where Molzym is headquartered

Location

Headquarters

HQ city
Bremen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Molzym business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel

Revenue model

  1. IVD Diagnostic Kits: Sale of CE IVD-marked diagnostic kits including SepsiTest™-UMD and Micro-Dx™ for culture-independent pathogen detection in clinical specimens. These kits include reagents for human DNA depletion, microbial DNA isolation, and 16S/18S PCR assays.
  2. Life Science Research Products: Sale of research-use products including MolYsis™ kits for host DNA depletion, DNA-free PCR reagents (MolTaq, Hot MolTaq, Mastermix), Ultra-Deep Microbiome Prep kits for NGS applications, and SelectNA™plus instruments.
  3. Services: Services include Mastermix Purification Service for decontamination of customer master mixes, Sequence Analysis Software (SepsiTest™ BLAST), and licensing opportunities for Molzym's technologies including host DNA removal methods and PCR decontamination know-how.
  4. Instrument Sales: Sale of SelectNA™plus robotic instruments for automated microbial DNA extraction. Instruments are sold alongside consumable kits for ongoing revenue.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for all products

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Molzym product offering

Product offering

Core offering

Molzym develops, manufactures, and sells molecular diagnostic kits, instruments, and reagents for culture-independent detection of bacterial and fungal pathogens. The portfolio centers on the proprietary MolYsis™ host DNA depletion technology combined with broad-range 16S/18S rRNA PCR assays, sold as CE IVD-marked clinical diagnostic products (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD) and as life science research kits (MolYsis™ Basic5, Ultra-Deep Microbiome Prep, DNA-free PCR reagents), supported by the SelectNA™plus automated extraction robot and the SepsiTest™ BLAST online identification software.

Product overview

Molzym offers a comprehensive portfolio of molecular diagnostic and life science products focused on culture-independent pathogen detection. The portfolio is organized into Clinical Diagnostics (CE IVD-marked products) and Life Science (research use products) categories. Key products include SepsiTest™-UMD CE IVD for manual molecular pathogen diagnosis, Micro-Dx™ CE IVD for automated diagnosis using the SelectNA™plus robot, and MolYsis-SN*plus*™ IVD for automated DNA isolation. The MolYsis™ technology platform enables host DNA depletion for improved molecular analysis. Supporting products include DNA-free PCR reagents (MolTaq, Hot MolTaq, Mastermix products), Ultra-Deep Microbiome Prep kits for NGS applications, and standard Taq DNA polymerases. Services include mastermix purification, sequence analysis software (SepsiTest™ BLAST), and licensing opportunities. The company was acquired by Bruker Corporation in late 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • SepsiTest™-UMD CE IVD CE IVD-marked molecular test kit for culture-independent detection and identification of bacterial and fungal pathogens in body fluids, tissues, and swabs via 16S and 18S rRNA gene PCR and Sanger sequencing, for clinical laboratories performing molecular infectious disease diagnostics.
  • Micro-Dx™ CE IVD Fully automated pathogen DNA enrichment and isolation system combining the SelectNA™plus robot with broad-range 16S and 18S PCR assays, designed for routine molecular diagnosis of bacterial and fungal pathogens in clinical laboratories.
  • MolYsis-SN*plus*™ IVD IVDR-compliant, fully automated kit for human DNA depletion and bacterial/fungal DNA isolation from diverse clinical specimens, used with the SelectNA™plus instrument for clinical diagnostic workflows.
  • SelectNA™plus Robot Bench-top robotic instrument for fully automated microbial DNA extraction from clinical specimens, with capacity for 1-12 samples per run and integrated UV decontamination.
  • MolYsis™ Basic5 Manual research-use kit for host DNA depletion from liquid biopsies (0.2-1 ml or 5 ml volumes), combinable with any microbial DNA isolation kit, for life science researchers.
  • MolYsis™ Complete5 Complete manual research-use kit combining host DNA depletion and microbial DNA isolation from liquid biopsies with validated protocols for life science researchers.
  • Ultra-Deep Microbiome Prep Research-use kit for host DNA depletion and microbial DNA isolation from 0.2-1 ml liquid samples or tissue specimens for next-generation sequencing (NGS) microbiome analysis.
  • Ultra-Deep Microbiome Prep10 Research-use kit for host DNA depletion and microbial DNA isolation from 1-10 ml liquid samples or tissue specimens for deeper NGS microbiome analysis.
  • MolYsis-SelectNA™plus Automated research-use kit for enrichment and isolation of microbial DNA from body fluids, tissues, and swabs using the SelectNA™plus robot.
  • DNA-Free PCR Reagents (MolTaq, Hot MolTaq, Mastermix 16S/18S Basic, Mastermix 16S/18S Dye, Mastermix 16S Complete, Mastermix 18S Complete, DNA-free Water) DNA-free PCR reagents line including MolTaq 16S/18S DNA polymerases, Hot MolTaq polymerase, Mastermix products (Basic, Dye, 16S Complete, 18S Complete), and PCR-grade DNA-free water, validated for up to 40 amplification cycles without false positive background.
  • MolTaq Standard PCR Reagents Standard highly processive Taq DNA polymerase for routine PCR applications with 5'-3' exonuclease activity, sold under the MolTaq brand.
  • UMD-Tubes Research-use cryo-protectant vials for long-term storage of clinical fluid samples at -70 to -80°C, protecting pathogens from freeze-thaw damage.
  • Mastermix Purification Service Custom service for setup and decontamination of customer master mixes, leveraging Molzym's DNA-free reagent expertise to ensure optimal assay performance without reagent contamination.
  • SepsiTest™ BLAST Sequence Analysis Software Free online BLAST bioinformatics tool for 16S and 18S rDNA sequence analysis, containing quality-edited full-length sequences of 7,042 cultivated bacteria and 342 cultivated fungi for species-level pathogen identification.
  • Technology Licensing Program Licensing program offering access to Molzym's proprietary host DNA removal methods and PCR decontamination know-how for assay development by partner companies.

Quantifiable outcome

  • 89% diagnostic sensitivity (95% CI: 83.8 to 94.2%) and 85% specificity (95% CI: 76.5 to 93.5%) in 409 comparative analyses
  • +3 more outcomes

Companies that use Molzym

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Molzym technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Molzym partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, minor and major.

  • Bruker CorporationcoreStrategic or Co-development Partner · 26 November 2025Molzym was acquired by Bruker Corporation in late 2025 (announced November 26, 2025). This acquisition strengthens Bruker's portfolio in molecular diagnostics and clinical research. Molzym operations continue as usual with same products, services, and supply processes. Contact emails updated to @bruker.com domain.
  • French Society of Microbiology (SFM)minorStrategic or Co-development Partner · 13 December 2022Partnership announced December 2022 to promote and stimulate the field of microbiology. Both organizations share desire to create synergies with experts to develop innovative and clinically relevant solutions for microbiology and infectious disease actors.
  • Fraunhofer IZI-BBminorStrategic or Co-development Partner · 2 December 2020Joint research and development project funded by European Regional Development Fund (ERDF) and federal state of Brandenburg (ILB) to develop automated sepsis diagnostic (AutoSepT) for fast testing in clinical laboratories.
  • Gradian DiagnosticsmajorStrategic or Co-development Partner · 16 December 2019Molzym joined Gradian Diagnostics in December 2019. Gradian is a holding company based in Miami, USA working on expanding diagnostic solutions through acquisitions. Molzym's team, locations, and operations remained unchanged following this acquisition.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Molzym competitors and assessment

Company assessment

Broad incumbents

  • Bruker Corporation: Parent company since late 2025 and broader life sciences tools and diagnostics company; MALDI Biotyper provides culture-based microbial ID that complements or competes with Molzym's culture-independent approach within the same microbiology workflows and customer base.
  • Cepheid (Danaher): Developer of the GeneXpert molecular diagnostics platform with broad syndromic panels for infectious disease; competes as a larger incumbent with established hospital sales channels and FDA-cleared pathogen detection assays serving similar clinical laboratory customers.
  • Hologic: Broad women's health and molecular diagnostics company with the Panther Fusion and Panther platforms for infectious disease testing; acquired Mobidiag in 2022 adding molecular GI infection diagnostics, positioning as a larger competitor in molecular pathogen detection.
  • Qiagen: Global molecular diagnostics and sample technologies company with the QIAstat-Dx syndromic panel system; competes as a broader incumbent offering pathogen detection workflows across multiple sample types and clinical indications, with overlapping customer base in clinical microbiology laboratories.

Direct peers

  • Q-linea: Swedish diagnostics company developing the ASTar system for rapid antimicrobial susceptibility testing directly from clinical samples; directly competes in culture-independent pathogen diagnostics for bloodstream infections with comparable technology positioning.
  • Accelerate Diagnostics: Maker of the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing (AST) directly from positive blood cultures; directly comparable as a rapid molecular/fluorometric diagnostics company targeting bloodstream infection diagnostics in similar clinical indications.
  • Karius: Developer of cell-free DNA next-generation sequencing-based pathogen detection from blood; directly comparable as an unbiased molecular pathogen diagnostics company serving similar clinical indications including sepsis and difficult-to-diagnose infections.
  • bioMérieux: Global leader in clinical microbiology diagnostics, including the BioFire FilmArray syndromic molecular panels and VITEK mass spectrometry ID; directly comparable as a microbiology-focused diagnostics company with overlapping pathogen detection offerings and similar hospital laboratory customers.
  • Specific Diagnostics: Developer of the REVEAL Rapid ID/AST system using proprietary volatile metabolomics for culture-free pathogen identification; overlaps with Molzym's culture-independent diagnostic approach for serious infections and similar hospital laboratory customers.
  • T2 Biosystems: Developer of T2 Magnetic Resonance-based molecular diagnostics for bloodstream infections (T2Bacteria, T2Candida); directly competes in culture-independent pathogen detection from whole blood with similar sepsis diagnostic value proposition and clinical workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Molzym social profiles

Digital presence

Molzym compliance and trust

Trust signal

Compliance2 records

Molzym financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molzym leadership team

Management profile

Number of profiles

Profiles7 records

Molzym funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molzym M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molzym

What does Molzym do?

Molzym develops, manufactures, and sells molecular diagnostic kits, instruments, and reagents for culture-independent detection of bacterial and fungal pathogens. The portfolio centers on the proprietary MolYsis™ host DNA depletion technology combined with broad-range 16S/18S rRNA PCR assays, sold as CE IVD-marked clinical diagnostic products (SepsiTest™-UMD, Micro-Dx™, MolYsis-SNplus™ IVD) and as life science research kits (MolYsis™ Basic5, Ultra-Deep Microbiome Prep, DNA-free PCR reagents), supported by the SelectNA™plus automated extraction robot and the SepsiTest™ BLAST online identification software.

Is Molzym a public or private company?

Molzym is a private company. It is classified as corporate owned and is currently operating.

When was Molzym founded?

Molzym was founded in 2003. It employs 11 to 50 people.

Where is Molzym based?

Molzym is headquartered in Bremen, Germany, in the Europe region.

How does Molzym make money?

Four revenue lines are on record. IVD Diagnostic Kits are the primary driver. The others are life Science Research Products, services and instrument Sales.

Who are Molzym's main competitors?

Broad incumbents on record are Bruker Corporation, Cepheid (Danaher), Hologic and Qiagen. Direct peers are Q-linea, Accelerate Diagnostics, Karius, bioMérieux, Specific Diagnostics and T2 Biosystems.

Does Molzym have an API?

No public API is recorded for Molzym.

What industry is Molzym in?

Molzym's product category is In Vitro Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals